score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2B	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2B Deletion		SC_9039	SC_9039-Tumor	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		SC_9039	SC_9039-Tumor	
Investigate Actionability - High	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Investigate Actionability - High	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Investigate Actionability - High	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9039	SC_9039-Tumor	
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						SC_9039		
Investigate Actionability - Low	Preclinical			Copy Number	FGFR2	Deletion				0.0	0.0		Investigate Actionability - Low	Infigratinib	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210												0				FGFR2 Deletion		SC_9039	SC_9039-Tumor	
Biologically Relevant				Somatic Variant	RAF1	Missense	p.P63L	0.3526	156.0	0.0	0.0																			0	334.0	0.3353	1.0	RAF1 p.P63L (Missense)		SC_9039	SC_9039-Tumor	SC_9039-Normal
Biologically Relevant				Copy Number	POT1	Amplification				0.0	0.0																			0				POT1 Amplification		SC_9039	SC_9039-Tumor	
Biologically Relevant				Copy Number	BCOR	Amplification				0.0	0.0																			0				BCOR Amplification		SC_9039	SC_9039-Tumor	
Biologically Relevant				Copy Number	RBM10	Amplification				0.0	0.0																			0				RBM10 Amplification		SC_9039	SC_9039-Tumor	
Biologically Relevant				Copy Number	ZRSR2	Amplification				0.0	0.0																			0				ZRSR2 Amplification		SC_9039	SC_9039-Tumor	
Biologically Relevant				Copy Number	STAG2	Amplification				0.0	0.0																			0				STAG2 Amplification		SC_9039	SC_9039-Tumor	
Biologically Relevant				Copy Number	CHEK1	Deletion				0.0	0.0																			0				CHEK1 Deletion		SC_9039	SC_9039-Tumor	
Biologically Relevant				Copy Number	NTRK3	Deletion				0.0	0.0																			0				NTRK3 Deletion		SC_9039	SC_9039-Tumor	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		SC_9039		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.562																							0				COSMIC Signature 1 (56%)		SC_9039		
